Pancreatic Cancer
Advertisement
Dr. Gulam A. Manji discusses CXCR4 and PD-1 inhibitors and how research has shown a potential benefit of the combination.
Dr. Gulam A. Manji discusses the ARC-8 study on quemliclustat plus gemcitabine/nab-paclitaxel with and without zimberelimab.
Drs. White and Berman consider how the post hoc analysis of CROSSFIRE elucidates the benefit of ablative therapy with IO.
Drs. White and Berman share insights gained from the CROSSFIRE trial comparing IRE with SBRT in advanced pancreatic cancer.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Chemoradiation, SABR, and irreversible electroporation can enhance outcomes and may be beneficial in certain circumstances.
Previous research has indicated that ABC factors should be utilized in the staging of localized PDAC.
Dr. Pant discusses the relationship between T cell response magnitude and tumor biomarker reduction.
Dr. Wainberg provides insight on the NAPOLI-3 study that compared NALIRIFOX against nab-paclitaxel plus gemcitabine.
Previous research has shown that quemliclustat 100 mg is the recommended dose for expansion.
GEMPAX did not meet the primary end point of OS, but the combination was found to improve PFS and ORR rates.
The NAPOLI 3 study demonstrated improved OS and PFS in patients with metastatic pancreatic cancer and no prior chemotherapy.
Future trials for resectable pancreatic ductal adenocarcinoma should be driven by patient biomarkers.
The ELI-002 vaccine uses T cells to identify and remove tumor cells containing KRAS G12D- or G12R-mutated cancer.
Dr. Abdilleh discusses PanCAN's new cloud-based data and analytics program for pancreatic cancer research.
Dr. Ethan Ludmir discusses the phase II EXTEND trial on MDT with systemic therapy for pancreatic ductal adenocarcinoma.
A subanalysis of the GENESECT study analyzed data from 50 gemcitabine monotherapy patients.
A recent study sought to better understand the association between EPI and development of pancreatic cancer.
The study evaluated the cost-effectiveness of combined MRI and EUS screening for populations at high risk for PDAC.
Dr. Harmeet Dhani highlights new research on the benefits of liquid biopsies for patients with pancreatic cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.